[{"orgOrder":0,"company":"Novadip Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novadip Biosciences receives IND approval from the FDA for regenerative bone product NVD-003","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"IND Enabling","country":"BELGIUM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling"},{"orgOrder":0,"company":"Novadip Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novadip Biosciences Reports Positive Data From phase I Study of NVD-001 For Spinal Fusion","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"BELGIUM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"Novadip Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novadip Biosciences Reports pOsitive Data from Phase I Study of NVD-001 for Spinal Fusion","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase I\/ Phase II","country":"BELGIUM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Novadip Biosciences","sponsor":"Science Ventures","pharmaFlowCategory":"D","amount":"$88.0 million","upfrontCash":"Undisclosed","newsHeadline":"Novadip Biosciences Raises Additional EUR 40 Million Bringing Total Company Funding to EUR 88 Million","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"BELGIUM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical"},{"orgOrder":0,"company":"Novadip Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novadip Biosciences SA Announces Positive Results from Phase 1\/2 Clinical Trial in Patients with Severe Bone Non-Union of the Lower Limb Following Trauma","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase I\/ Phase II","country":"BELGIUM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Novadip Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novadip Biosciences SA Announces First Pediatric Patient with Congenital Pseudoarthrosis of the Tibia Undergoes Implantation with NVD-003, an Autologous Tissue Regeneration Product, in Phase 1b\/2a US\/EU Clinical Trial","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase I\/ Phase II","country":"BELGIUM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II"}]
Find Clinical Drug Pipeline Developments & Deals by Novadip Biosciences
NVD-003 is an autologous therapy derived from adipose stem cells, which reverses severe bone deterioration and to achieve accelerated ossification, is being investigated as a single treatment to save limbs and restore mobility in patients with CPT.
NVD-003, an autologous tissue engineered product generated from the patients’ own adipose stem cells, was applied in nine patients with bone non-union of the lower limb who had previously undergone several surgical procedures.
NVD-X3 is an allogeneic therapeutic that can provide accelerated, durable bone union in spinal fusion procedures and non-healing fractures, and NVD-003 is an autologous bone engraftment product designed to provide a single treatment cure for critical size bone defects.
NVD-001 is Novadip’s first generation autologous cell-based osteogenic (bone healing) product derived from the Company’s proprietary tissue regeneration platform. Study met its primary endpoint. NVD-001 showed a favorable safety profile over a two-year observation period.
NVD-001 is Novadip’s first generation autologous cell-based osteogenic (bone healing) product derived from the Company’s proprietary tissue regeneration platform.
NVD-003 is a novel autologous cell-based osteogenic (bone healing) product that has been generated from Novadip’s proprietary tissue regeneration platform. Made from adipose stem cells, NVD-003 has a 3-dimensional structure and works by promoting bone formation.